Last10K.com

Allogene Therapeutics, Inc. (ALLO) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

ALLO Annual Reports

  • 10-K Annual Report February 2022
  • 10-K Annual Report February 2021
    10-K Annual Report February 2020
    10-K Annual Report March 2019

Allogene Therapeutics, Inc.

CIK: 1737287 Ticker: ALLO
Cover Page - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Feb. 21, 2022
Jun. 30, 2021
Cover [Abstract]   
Document Type10-K  
Document Annual Reporttrue  
Document Period End DateDec. 31, 2021  
Current Fiscal Year End Date--12-31  
Document Transition Reportfalse  
Entity File Number001-38693  
Entity Registrant NameAllogene Therapeutics, Inc.  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number82-3562771  
Entity Address, Address Line One210 East Grand Avenue  
Entity Address, City or TownSouth San Francisco  
Entity Address, State or ProvinceCA  
Entity Address, Postal Zip Code94080  
City Area Code650  
Local Phone Number457-2700  
Title of 12(b) SecurityCommon Stock, Par Value $0.001 Per Share  
Trading SymbolALLO  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerYes  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryLarge Accelerated Filer  
Entity Small Businessfalse  
Entity Emerging Growth Companyfalse  
ICFR Auditor Attestation Flagtrue  
Entity Shell Companyfalse  
Entity Public Float  $ 2,254
Entity Common Stock, Shares Outstanding (in shares) 142,752,002 
Documents Incorporated by ReferencePortions of the Registrant’s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Report.  
Amendment Flagfalse  
Entity Central Index Key0001737287  
Document Fiscal Year Focus2021  
Document Fiscal Period FocusFY  
Auditor NameErnst & Young LLP  
Auditor LocationRedwood City, California  
Auditor Firm ID42  

View differences made from one year to another to evaluate Allogene Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allogene Therapeutics, Inc..

Continue

Assess how Allogene Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Allogene Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Geography
Product
Shares
Other
Inside Allogene Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders??? Equity (Deficit)
Consolidated Statements Of Convertible Preferred Stock And Stockholders??? Equity (Deficit) (Parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
401(K) Plan
401(K) Plan (Details)
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Additional Information (Details)
Balance Sheet Components - Schedule Of Accrued Liabilities (Details)
Balance Sheet Components - Schedule Of Property And Equipment, Net (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Lease Costs (Details)
Commitments And Contingencies - Lease Liabilities (Details)
Commitments And Contingencies - Summary Of Undiscounted Future Non-Cancellable Lease Payments Under Operating Leases (Details)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (Policies)
Description Of Business And Summary Of Significant Accounting Policies (Tables)
Description Of Business And Summary Of Significant Accounting Policies - Additional Information (Details)
Description Of Business And Summary Of Significant Accounting Policies - Schedule Of Estimated Life Of Assets (Details)
Equity Method Investment
Equity Method Investment (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Financial Assets Measured At Fair Value On Recurring Basis (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Schedule Of Income Tax Reconciliation (Details)
Income Taxes - Schedule Of Reconciliation Of Unrecognized Tax Benefits (Details)
Income Taxes - Summary Of Operating Loss Carryforwards And Tax Credits (Details)
Income Taxes - Summary Of Valuation Allowance (Details)
Investment (Tables)
Investment - Additional Information (Details)
Investments
Investments - Schedule Of Fair Values Of Available For Sale Debt Investments By Contractual Maturity (Detail)
Investments - Summary Of Cash Equivalents, Restricted Cash And Investments, Classified As Available-For-Sale Securities (Details)
License And Collaboration Agreements
License And Collaboration Agreements (Details)
Net Loss And Net Loss Per Share
Net Loss And Net Loss Per Share (Tables)
Net Loss And Net Loss Per Share - Schedule Of Anti-Dilutive Shares (Details)
Net Loss And Net Loss Per Share - Schedule Of Earnings Per Share Basic And Diluted (Details)
Recent Accounting Guidance
Related Party Transactions
Related Party Transactions (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Schedule Of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)
Stock-Based Compensation - Schedule Of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)
Stock-Based Compensation - Schedule Of Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Stock Option Activity (Details)
Stock-Based Compensation - Summary Of Restricted Stock Activity (Details)
Stockholders' Equity
Stockholders' Equity (Details)
Subsequent Events
Subsequent Events (Details)
Ticker: ALLO
CIK: 1737287
Form Type: 10-K Annual Report
Accession Number: 0001737287-22-000013
Submitted to the SEC: Wed Feb 23 2022 4:11:51 PM EST
Accepted by the SEC: Wed Feb 23 2022
Period: Friday, December 31, 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/allo/0001737287-22-000013.htm